Stromal vascular fraction promotes fibroblast migration and cellular viability in a hyperglycemic microenvironment through up-regulation of wound healing cytokines.
Tan SS., Yeo XY., Liang ZC., Sethi SK., Tay SSW.
Animal Study with a reported sample of 3 on Diabetic Foot, Chronic Wound, published in Exp Mol Pathol (2018) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Exp Mol Pathol (2018)
- Country
- Netherlands
- Reported sample size
- 3
- Source database
- PubMed
- PMID
- 29621477
- DOI
- 10.1016/j.yexmp.2018.03.007
- Citations
- 19
Abstract (original English)
Diabetic wounds have impaired healing and a propensity for further morbidity, which may result in amputations. Stromal vascular fraction (SVF) is an autologous source of heterogeneous cell population obtained from adipose tissue, which is rich in stem cells and presents little immunogenicity to the host. In this study, we hypothesized that murine fibroblasts subjected to hyperglycemic conditions co-treated with SVF exhibit greater functional activity through the colorimetric MTT assay and a cell-monolayer in-vitro scratch assay. We sought to establish the underlying mechanism of action via the utility of an ELISA chemiluminescence array on the supernatant medium of the cells. Our results demonstrate that the mean percentage gap closure at 24 h in the hyperglycemia + SVF group was significantly greater at 41.1% ± 1.6% compared to the hyperglycemia alone group 16.6% ± 1.5% (post-hoc Bonferroni test p < 0.001, n = 3) although there was no difference between the SVF and normoglycemia group. Further, this SVF group exhibited a significantly greater 2.4 fold increase in fibroblastic cell viability as compared to the hyperglycemia alone group (p = 0.001, n = 3). The supernatant medium of the cells upon testing with ELISA indicated that early phase wound healing cytokines including platelet-derived growth factor (p = 0.012, n = 3), interleukin-1 (p = 0.003, n = 3), basic fibroblast gro
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisPubMed
Efficacy of Stem Cell-Derived Exosomes in Promoting Diabetic Foot Ulcer Healing: A Meta-Analysis of Preclinical Animal Studies.
Meta-analysis on Diabetic Foot, Chronic Wound, published in J Diabetes Res (2026) — summary generated from the PubMed abstract.
- 2026
J Diabetes Res - Level AMeta-analysisEurope PMC
Bone marrow-derived mesenchymal stem cells combined with intramuscular injection promote the healing of diabetic foot ulcers: a systematic review and meta-analysis
Meta-analysis with a reported sample of 2059 on Diabetic Foot, Chronic Wound, published in Front Endocrinol (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
- n = 2059
Front Endocrinol (Lausanne) - Level AMeta-analysisEurope PMC
Comparative efficacy of advanced therapeutic modalities for diabetic foot ulcers: a systematic review and meta-analysis including NPWT, stem cells, ESWT, and bioengineered treatments
Meta-analysis on Diabetic Foot, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.
- 2026
Front Bioeng Biotechnol - Level AMeta-analysisPubMed
Therapeutic potential of adipose-derived stem cells for diabetic foot ulcers: a systematic review and meta-analysis.
Meta-analysis on Diabetic Foot, Chronic Wound, published in Diabetol Metab Syndr (2025) — summary generated from the PubMed abstract.
- 2025
Diabetol Metab Syndr6 citations - Level AMeta-analysisPubMed
A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus.
Meta-analysis on Diabetic Foot, Autoimmune Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
- 2025
Stem Cell Res Ther - Level AMeta-analysisEurope PMC
Comparison of the efficacy of 12 interventions in the treatment of diabetic foot ulcers: a network meta-analysis
Meta-analysis with a reported sample of 356 on Diabetic Foot, Chronic Wound, published in PeerJ (2025) — summary generated from the PubMed abstract.
- 2025
- n = 356
PeerJ1 citations